Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Investment Research • Jul 3, 2026

Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus' investigational mRNA therapy for Cystic Fibrosis. The collaboration will leverage Thermo.

Business Wire • Jul 2, 2026

Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is collaborating with Thermo Fisher Scientific Inc. (NYSE:TMO) to support the Phase 3 development and potential commercialization of ARCT-032, the company's investigational messenger RNA therapy for cystic fibrosis.

Benzinga • Jul 2, 2026

Arcturus could halve the grid's electrical losses using its nano-infused copper

The world uses a lot of copper, but thanks to the energy transition and data centers, it'll need a lot more. Between now and 2050, we'll have to produce more copper than has been mined throughout all of human history, according to one study.

TechCrunch • Jun 30, 2026

Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies

Arcturus Therapeutics NASDAQ: ARCT President and CEO Joseph Payne outlined the company's messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies Global Healthcare Conference in New York.

MarketBeat • Jun 5, 2026

Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript

Seeking Alpha • Jun 5, 2026

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics will present at 2026 Jefferies Global Healthcare Conference.

Business Wire • May 26, 2026

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31, 2026, and provided corporate updates. “Arcturus continues to advance its rare disease therapeutics portfolio. We have initiated enrollment of our 12‑week CF Phase 2 study in the first quarter of 2026, earlier.

Business Wire • May 7, 2026

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $0.52 per share a year ago.

Zacks Investment Research • May 7, 2026